cerapedics.comHealthcare / BioTech & PharmaFounded: 2000Funding to Date: $311.92MM
Cerapedics is a biotech company that aims to develop commercialized OrthoBiologics products to improve and expedite bone formation. With a mission to enhance bone repair and interventional procedures, Cerapedics features products such as the i-FACTOR and P-15 with the aim for patients to live healthier lives. Cerapedics was founded by Andrew Tofe in 2021 and is headquartered in Denver, CO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/05/2024 | Series G | $15.23MM | $xx.xx | $744.31MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,700,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|
||||||
02/18/2022 | Series F | $54.72MM | $xx.xx | $742.79MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
9,700,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|
||||||
07/06/2018 | Series E | $22MM | $xx.xx | $157.19MM | Kck Group | |
Price per Share
$xx.xx
Shares Outstanding
17,240,027
Liquidation Pref Order
1
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
1000
Key Investors
Kck Group
|
||||||
09/29/2016 | Series D | $15.2MM | $xx.xx | $131.48MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
11,911,292
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|
||||||
12/12/2012 | Series C | $23.86MM | $xx.xx | $125.32MM | Cvf Llc, Medimmune Ventures, Ngn Capital, Orbimed Advisors | |
Price per Share
$xx.xx
Shares Outstanding
17,044,936
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
1000
Key Investors
Cvf Llc, Medimmune Ventures, Ngn Capital, Orbimed Advisors
|
||||||
04/06/2009 | Series B | $18.1MM | $xx.xx | $84.08MM | Ngn Capital, Orbimed Advisors | |
Price per Share
$xx.xx
Shares Outstanding
13,256,314
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
1000
Key Investors
Ngn Capital, Orbimed Advisors
|
||||||
10/05/2007 | Series A | $14.46MM | $xx.xx | $48.19MM | Orbimed Advisors | |
Price per Share
$xx.xx
Shares Outstanding
14,457,000
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
1000
Key Investors
Orbimed Advisors
|